Compare ResMed Inc. (RMD) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Williams Companies Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Williams Companies Inc trades at $75.31 (market cap $92.75B). The key difference: Williams Companies Inc is far larger — about 2.9× ResMed Inc.'s market cap, and Williams Companies Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| RMD | WMB | |
|---|---|---|
Market Cap | $31.89B | $92.75B |
Sector | Health | Energy |
52-Week High | $283.28 | $79.40 |
52-Week Low | $182.82 | $56.51 |
Enterprise Value | $31.24B | $123.38B |
Dividend Yield | 1.19% | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
WMB trades at $75.83, up 2.27% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q2 2026 earnings but maintains robust profitability with a 25.18% net income margin. Recent developments include the $5.5 billion acquisition of Momentum Midstream, enhancing its natural gas infrastructure, while a court ruling vacated a key permit for the NESE pipeline project.
The stock offers growth exposure to natural gas demand driven by LNG exports and AI infrastructure, with a consensus price target of $88.14 implying 16% upside. Risks include regulatory hurdles for pipeline projects and high debt levels, but strong cash flow supports dividends and expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
